This Benefits Canada article highlights how private insurers can benefit from aligning with provincial biosimilars policies.
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
This Benefits Canada article highlights the importance of maximizing the use of biosimilar and generic medicines to ensure plan sustainability.
Biosimilars Canada is participating in this globally aligned educational initiative to raise awareness of biosimilar medicines from November 16 to 20.
A new study by the Ontario Drug Policy Research Network found that provinces could save up to $426 million by implementing biosimilar switching policies.
Op-ed in Advantages magazine by Jim Keon, President of the Canadian Generic Pharmaceutical Association and its Biosimilars Canada division, which highlights the benefits of expanding the use of generic and biosimilar medicines for group drug benefit plans. Available in French only.
Alberta is expanding its biosimilars program by switching Rituxan rituximab patients to biosimilars. The Province has also added coverage for three new biosimilars.